Clicky

InDex Pharmaceuticals Holding AB(INDEX)

Description: InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis. The company's lead drug candidate is Cobitolimod, which is in phase III clinical development for the treatment of patients with moderate to severe ulcerative colitis. It also develops a portfolio of other DNA based immunomodulatory sequences in preclinical stage for the treatment of various immunological diseases. The company was founded in 2000 and is headquartered in Solna, Sweden.


Keywords: Medicine Clinical Medicine Pharmaceutical Products Immunotherapy Autoimmune Disease Monoclonal Antibodies Ulcerative Colitis Diarrhea Colitis Pharmaceutical Development Immunological Diseases Abivax

Home Page: www.indexpharma.com

Berzelius vAeg 13
Solna, 171 65
Sweden
Phone: 46 8 12 20 38 50


Officers

Name Title
Mr. Johan Gileus Acting CEO & CFO
Dr. Charlotte Admyre Chief Scientific Officer
Ms. Margareth Jorvid Head of Regulatory Affairs
Ms. Eva Arlander Chief Devel. Officer
Dr. Anders Broijersen Chief Medical Officer

Exchange: ST

Country: SE : Sweden

Currency: Swedish krone (kr)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.2191
Price-to-Sales TTM: 7.4385
IPO Date:
Fiscal Year End: December
Full Time Employees: 7
Back to stocks